Current Releases

bulletASCENSIA DIABETES CARE RECEIVES FDA CLEARANCE FOR THE APP-ENABLED CONTOUR® NEXT ONE BLOOD GLUCOSE MONITORING SYSTEM

Parsippany, November 21, 2016
Ascensia Diabetes Care announced it has received U.S. Food and Drug Administration (FDA) 510(k) clearance for the CONTOUR® NEXT ONE Blood Glucose Monitoring System (BGMS), marking a key step in making the next-generation system available to people living with diabetes in the U.S.

bulletASCENSIA DIABETES CARE LAUNCHES CONTOUR® NEXT LINK 2.4 WIRELESS BLOOD GLUCOSE MONITORING SYSTEM AS PART OF THE MEDTRONIC MINIMED® 630G SYSTEM WITH SMARTGUARD TECHNOLOGY

Parsippany, August 11, 2016
Ascensia Diabetes Care has today announced the commercial launch and approval from the U.S. Food and Drug Administration (FDA) of the CONTOUR®NEXT LINK 2.4 Blood Glucose Monitoring System (BGMS) as part of the Medtronic MiniMed® 630G system with SmartGuard technology.

bulletBayer to divest Diabetes Care business to Panasonic Healthcare Holdings Co., Ltd. for EUR 1,022 million

Leverkusen, June 10, 2015
Bayer AG has entered into a definitive agreement to sell its Diabetes Care business to Panasonic Healthcare Holdings Co., Ltd., a company which is backed by funds sponsored by leading global investment firm KKR and the Panasonic Corporation.